{"meta":{"query_hash":"50eb5e19ceec","filters":{"venue":"Clinical Medicine Therapeutics"},"cohort_total":6,"direct_labels_cover":0,"predictions_cover":6,"exported":6,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/50eb5e19ceec","api":"https://metacan.xera.ac/api/v1/cohort?venue=Clinical+Medicine+Therapeutics"},"results":[{"id":"W1515768733","doi":"10.4137/cmt.s1958","title":"Metastatic Bone Disease in Patients with Solid Tumors–-Burden of Bone Disease and the Role of Zoledronic Acid","year":2009,"lang":"en","type":"article","venue":"Clinical Medicine Therapeutics","topic":"Bone health and treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital","funders":"","keywords":"Medicine; Zoledronic acid; Bisphosphonate; Breast cancer; Multiple myeloma; Spinal cord compression; Bone disease; Cancer; Malignancy; Bone pain; Oncology; Internal medicine; Bone metastasis; Disease; Surgery; Osteoporosis; Spinal cord","score_opus":0.030077718762179753,"score_gpt":0.3639025478008038,"score_spread":0.33382482903862404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1515768733","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45804122,0.49031556,0.0014103972,0.021736618,0.00061636587,0.000104205246,0.0007692415,0.00003390035,0.026972516],"genre_scores_gemma":[0.9214335,0.073325925,0.00085544767,0.0012972982,0.0011213821,0.00003209171,0.00030395313,0.000004324406,0.0016261458],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9997898,0.00009621679,0.000021213953,0.000016608361,0.00005950491,0.000016730577],"domain_scores_gemma":[0.9996884,0.00009749364,0.00009913052,0.000008035489,0.000040219773,0.00006674497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004761531,0.00014453358,0.0004762423,0.00031850743,0.00015469447,0.00042289816,0.000114234856,0.00025320298,0.0028326078],"category_scores_gemma":[0.0013090221,0.00006739684,0.00030198542,0.0005126533,0.00016364436,0.00030172442,0.00022606763,0.00038944994,0.000240334],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008004643,0.00051162555,0.29337522,0.0025476734,0.00064006,0.002233604,0.00021978041,0.0014355873,0.0071671708,0.0066660903,0.016614813,0.6605838],"study_design_scores_gemma":[0.0011798766,0.005825251,0.8950825,0.0010116552,0.00078848,0.014824416,0.00046107898,0.0017050199,0.0012446594,0.0070711663,0.07076408,0.000041833682],"about_ca_topic_score_codex":0.0013148542,"about_ca_topic_score_gemma":0.0028269002,"teacher_disagreement_score":0.0028326078,"about_ca_system_score_codex":0.0003431614,"about_ca_system_score_gemma":0.0005341481,"threshold_uncertainty_score":0.009476066},"labels":[],"label_agreement":null},{"id":"W1523887359","doi":"10.4137/cmt.s32","title":"Raltegravir: Its use in the Treatment of HIV Infection","year":2009,"lang":"en","type":"article","venue":"Clinical Medicine Therapeutics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital","funders":"","keywords":"Raltegravir; Medicine; Integrase inhibitor; Context (archaeology); Pharmacology; Drug; Clinical trial; Human immunodeficiency virus (HIV); Integrase; Antiretroviral therapy; Intensive care medicine; Virology; Viral load; Internal medicine","score_opus":0.18152407667860665,"score_gpt":0.4358891105728506,"score_spread":0.254365033894244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1523887359","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10354614,0.650368,0.040236067,0.022690384,0.0032631333,0.0006493378,0.001783897,0.0043527097,0.17311038],"genre_scores_gemma":[0.50439453,0.36350837,0.039647713,0.008198221,0.0031346085,0.00024755846,0.0014378785,0.00040754364,0.079023615],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99980456,0.000044532557,0.000013915707,0.00002599023,0.00008307551,0.000027975235],"domain_scores_gemma":[0.99990344,0.000012827831,0.00001607872,0.000010224849,0.00002105686,0.000036259473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041850517,0.00030323176,0.00041362748,0.00047406575,0.00027943196,0.00059513445,0.00040482168,0.0006971921,0.0037477417],"category_scores_gemma":[0.00046133378,0.00013415342,0.00018937963,0.00055942824,0.0003766203,0.0003007184,0.00061314163,0.0008956929,0.0035700644],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033127755,0.00013757097,0.00063778064,0.00054729026,0.000013629622,0.0005364445,0.000071544375,0.0001971143,0.011455024,0.002139459,0.025547337,0.9583856],"study_design_scores_gemma":[0.00032682827,0.0008416862,0.0039567687,0.0003272891,0.00006971861,0.011543524,0.00005156415,0.0007144777,0.015578972,0.0016995908,0.9648597,0.000029927149],"about_ca_topic_score_codex":0.0007232474,"about_ca_topic_score_gemma":0.0008109269,"teacher_disagreement_score":0.0037477417,"about_ca_system_score_codex":0.0002798009,"about_ca_system_score_gemma":0.0005334127,"threshold_uncertainty_score":0.01253742},"labels":[],"label_agreement":null},{"id":"W1557785974","doi":"10.4137/cmt.s1088","title":"Pharmacotherapy of HIV: A Focus on Atazanavir/Ritonavir a Potent and Convenient Once Daily Ritonavir Boosted Protease-Inhibitor for HIV-1 Infected Adults","year":2009,"lang":"en","type":"article","venue":"Clinical Medicine Therapeutics","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Ritonavir; Atazanavir; Tolerability; Medicine; Lopinavir; Protease inhibitor (pharmacology); Pharmacology; Cobicistat; Discontinuation; Darunavir; Adverse effect; Viral load; Pharmacotherapy; Internal medicine; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy","score_opus":0.053827536458433196,"score_gpt":0.38340906998960606,"score_spread":0.32958153353117287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1557785974","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008747993,0.9148155,0.003876756,0.0459606,0.0021209752,0.00011373514,0.000055114753,0.000118139804,0.02419128],"genre_scores_gemma":[0.03213364,0.92493826,0.0059583727,0.018421674,0.010128904,0.000088720066,0.00006839266,0.000041794563,0.008220268],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99965155,0.00013602637,0.000033225766,0.000048824466,0.000091312286,0.000039068585],"domain_scores_gemma":[0.9994603,0.00022628419,0.000045336405,0.000022294973,0.00013205399,0.000113746704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010196762,0.00048227198,0.0007900112,0.000816017,0.00033805662,0.0010972808,0.0004186921,0.0013330836,0.0033535555],"category_scores_gemma":[0.00064427423,0.00017265172,0.0003801218,0.00063227816,0.0006427535,0.001617104,0.0007919039,0.0018673358,0.00073440553],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021902088,0.00039969716,0.0011328976,0.0029084538,0.00005907552,0.0013277063,0.0001869521,0.00042906997,0.0045094015,0.008199651,0.039354485,0.9412735],"study_design_scores_gemma":[0.00024377166,0.0016073916,0.01223668,0.0023935633,0.00009437682,0.0070565157,0.00023282603,0.000746742,0.0011512515,0.0054729627,0.9687141,0.000049720762],"about_ca_topic_score_codex":0.0010142119,"about_ca_topic_score_gemma":0.0037993074,"teacher_disagreement_score":0.0033535555,"about_ca_system_score_codex":0.000684186,"about_ca_system_score_gemma":0.0009311133,"threshold_uncertainty_score":0.011218786},"labels":[],"label_agreement":null},{"id":"W1607081374","doi":"10.4137/cmt.s3410","title":"A Review of the Impact of Lapatinib on Health-Related Quality of Life in the Management of Advanced solid Tumors","year":2009,"lang":"en","type":"review","venue":"Clinical Medicine Therapeutics","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"","keywords":"Lapatinib; Medicine; Quality of life (healthcare); Clinical trial; Metastatic breast cancer; Epidermal growth factor receptor; Breast cancer; Oncology; Internal medicine; Cancer; Trastuzumab","score_opus":0.3530756171237509,"score_gpt":0.6077769786051451,"score_spread":0.2547013614813942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1607081374","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000079776255,0.99932444,0.000038039867,0.00010610334,0.000064779924,0.0000050420813,0.000018131966,0.0000022134489,0.00036160747],"genre_scores_gemma":[0.0003423459,0.9993144,0.00010505373,0.00008095101,0.000037099737,0.000004421784,0.000014585453,4.6796012e-7,0.00010073882],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99965286,0.00008928328,0.00008679494,0.00003788945,0.00011741462,0.000015801228],"domain_scores_gemma":[0.9993388,0.00037312726,0.000112512855,0.000010440763,0.00013507337,0.000030019753],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000803732,0.0007480896,0.0019448022,0.0032451537,0.00025387717,0.0008153174,0.0007383596,0.00070566277,0.0034017896],"category_scores_gemma":[0.0012886905,0.00027500864,0.00076462235,0.0044714883,0.000283638,0.00096485135,0.0004385808,0.0008712544,0.0009012462],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001005832,0.000052667237,0.00015490055,0.09432818,0.0002508835,0.00019287928,0.00007396847,0.00024067913,0.0008001122,0.0011060497,0.022827545,0.8798714],"study_design_scores_gemma":[0.00007143494,0.0002829354,0.0034083994,0.06268686,0.0012243919,0.0024218617,0.00017400896,0.000163277,0.0005204777,0.0015444935,0.92746055,0.00004132181],"about_ca_topic_score_codex":0.0016813668,"about_ca_topic_score_gemma":0.0040575294,"teacher_disagreement_score":0.0034017896,"about_ca_system_score_codex":0.0006489646,"about_ca_system_score_gemma":0.0016501758,"threshold_uncertainty_score":0.011380136},"labels":[],"label_agreement":null},{"id":"W178606676","doi":"10.4137/cmt.s2095","title":"Reduction in Risk of Myocardial Infarction, Stroke, and Death from Cardiovascular Causes. Focus on Rampiril","year":2009,"lang":"en","type":"article","venue":"Clinical Medicine Therapeutics","topic":"Blood Pressure and Hypertension Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Ramipril; Medicine; Myocardial infarction; Cardiology; Diabetes mellitus; Stroke (engine); Internal medicine; ACE inhibitor; Heart failure; Angiotensin-converting enzyme; Infarction; Endocrinology; Blood pressure","score_opus":0.09543285235239683,"score_gpt":0.36400491909620747,"score_spread":0.2685720667438106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W178606676","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12761414,0.8357513,0.0011509462,0.0032781137,0.000727111,0.00018335087,0.0014410693,0.00011698153,0.02973702],"genre_scores_gemma":[0.40626705,0.57932127,0.00309741,0.0028162354,0.0010694592,0.00012146782,0.00085953425,0.000020088182,0.00642752],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99982613,0.00007781923,0.000019032323,0.000022727063,0.000044413744,0.000009814506],"domain_scores_gemma":[0.9998006,0.000073276824,0.000054548582,0.0000130404715,0.000027832648,0.000030638228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005123714,0.00030717909,0.00069720973,0.0003220178,0.000087188404,0.00022671476,0.00021058327,0.0001754621,0.005919074],"category_scores_gemma":[0.0005576212,0.0000679346,0.00042466534,0.00022748974,0.00008036564,0.00014211088,0.0001770989,0.000754694,0.00061575876],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045217713,0.0013576549,0.004266383,0.010509229,0.0014954185,0.00020676105,0.000067571615,0.00015484255,0.017030342,0.00093488133,0.0063970094,0.9530581],"study_design_scores_gemma":[0.0096606035,0.07182133,0.5102453,0.007635511,0.01563011,0.0056930226,0.0004117201,0.00066766026,0.030131068,0.0030591409,0.34493485,0.00010963064],"about_ca_topic_score_codex":0.00021594323,"about_ca_topic_score_gemma":0.00070046476,"teacher_disagreement_score":0.005919074,"about_ca_system_score_codex":0.000074550684,"about_ca_system_score_gemma":0.00016522149,"threshold_uncertainty_score":0.019801259},"labels":[],"label_agreement":null},{"id":"W182841154","doi":"10.4137/cmt.s1086","title":"Safety and Efficacy of Ivabradine in the Management of Stable Angina Pectoris","year":2009,"lang":"en","type":"article","venue":"Clinical Medicine Therapeutics","topic":"Heart rate and cardiovascular health","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Heart Institute","funders":"","keywords":"Ivabradine; Medicine; Cardiology; Internal medicine; Coronary artery disease; Angina; Inotrope; Heart rate; Myocardial infarction; Blood pressure","score_opus":0.07700973914686307,"score_gpt":0.41000020468969134,"score_spread":0.3329904655428283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W182841154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7663875,0.2149503,0.002160275,0.00410638,0.0007428705,0.00067613873,0.0009823425,0.00011292949,0.00988131],"genre_scores_gemma":[0.9619604,0.03055281,0.001513609,0.0024955298,0.00087469316,0.0002907349,0.00071167754,0.000018357037,0.0015821769],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99922884,0.00040213842,0.000089079425,0.00007985957,0.00015285944,0.00004726842],"domain_scores_gemma":[0.99850035,0.00048256046,0.00050183444,0.000094060364,0.00019697283,0.0002242152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019228514,0.00020363268,0.0010871529,0.00023393544,0.00019455882,0.0005864229,0.00034490545,0.00068064453,0.0014000889],"category_scores_gemma":[0.0030613001,0.00009743487,0.0006822255,0.00031497324,0.00033147796,0.00028617718,0.00015855304,0.001318894,0.00028276155],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12805063,0.006162081,0.014225713,0.0034292173,0.0008667728,0.00057040504,0.00023468903,0.00083821075,0.024730228,0.00079138495,0.0040217983,0.81607896],"study_design_scores_gemma":[0.16151245,0.4722585,0.25260094,0.0030763561,0.0024372924,0.003511311,0.00038876233,0.004068751,0.013526951,0.0026980527,0.083781764,0.00013886644],"about_ca_topic_score_codex":0.0003610902,"about_ca_topic_score_gemma":0.0005057245,"teacher_disagreement_score":0.0019228514,"about_ca_system_score_codex":0.00032903347,"about_ca_system_score_gemma":0.00040818454,"threshold_uncertainty_score":0.010169089},"labels":[],"label_agreement":null}]}